Clinical Trials
41 trialsTITAN
Aragon Pharmaceuticals, Inc.
PROTEUS
Janssen Research & Development, LLC
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
LIBERTAS
Janssen Research & Development, LLC
DIRECT
University Health Network, Toronto
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
University of Wisconsin, Madison
ARPEGGIO
Brigham and Women's Hospital
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
HAYATE
Bayer
EvoPAR-PR02
AstraZeneca
RADVAN
Sun Yat-sen University
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
TRAP
Royal Marsden NHS Foundation Trust
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
KNIGHTS
University of Maryland, Baltimore
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
KEYNOTE-991
Merck Sharp & Dohme LLC
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Washington University School of Medicine
GETUG-AFU 40
UNICANCER
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
R-Pharm
Prostate005
University of Virginia
China ARCHES
Astellas Pharma Inc
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
ASCENDE-SBRT
Canadian Cancer Trials Group
VA STARPORT
VA Office of Research and Development
HARMONY
Hoosier Cancer Research Network
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
OMPC-RPM
Fudan University
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
PRO-BOOST-N
Affidea Nu-med Center of Oncological DIagnostics and Therapy
HYP-OP-RT
CHU de Quebec-Universite Laval
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences